Interleukin (IL)-17 is recognized to play a critical role in numerous immune and inflammatory responses by regulating the expression of various inflammatory mediators, which include cytokines, chemokines, and adhesion molecules. There is growing evidence that IL-17 is involved in the pathogenesis of asthma. IL-17 orchestrates the neutrophilic influx into the airways and also enhances T-helper 2 (Th2) cell-mediated eosinophilic airway inflammation in asthma. Recent studies have demonstrated that not only inhibitor of IL-17 per se but also diverse regulators of IL-17 expression reduce antigen-induced airway inflammation, bronchial hyperresponsiveness, and Th2 cytokine levels in animal models of asthma. This review will summarize the role of IL-17 in the context of allergic airway inflammation and discuss the therapeutic potential of various strategies targeting IL-17 for asthma.© 2010 Park and Lee; licensee BioMed Central Ltd.
CITATION STYLE
Park, S. J., & Lee, Y. C. (2010, June 16). Interleukin-17 regulation: An attractive therapeutic approach for asthma. Respiratory Research. https://doi.org/10.1186/1465-9921-11-78
Mendeley helps you to discover research relevant for your work.